Table 6.
ACR50 and mPsARC response rates at week 12 in patients with PsA stratified by prior anti-TNF therapy
| ACR50 | mPsARC | |||||
|---|---|---|---|---|---|---|
| Response rate, | Unadjusted odds ratio | P value | Response rate, | Unadjusted odds ratio | P value | |
| n/N (%) | (95% CI) | n/N (%) | (95% CI) | |||
| History of prior anti-TNF therapy | ||||||
| Prior ETN or IFX or both | 25/60 (41.7) | 0.65 (0.37 to 1.13) | 0.130 | 42/59 (71.2) | 0.66 (0.36 to 1.23) | 0.194 |
| No prior ETN/IFXa | 182/348 (52.3) | 272/345 (78.8) | ||||
aUsed as reference value. ACR50, American College of Rheumatology 50% or more improvement; CI, confidence interval; ETN, etanercept; IFX, infliximab; mPsARC, modified Psoriatic Arthritis Response Criteria; PsA, psoriatic arthritis.